Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Rating Upgraded by BidaskClub

Share on StockTwits

Tabula Rasa HealthCare (NASDAQ:TRHC) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports.

TRHC has been the topic of a number of other reports. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. Piper Jaffray Companies increased their price objective on shares of Beigene to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, May 9th. Guggenheim began coverage on shares of Patterson Companies in a research note on Wednesday, April 17th. They set a “neutral” rating and a $23.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a research note on Monday, May 13th. They set an “overweight” rating and a $21.00 price objective on the stock. Finally, TheStreet downgraded shares of Twin Disc from a “b-” rating to a “c+” rating in a research note on Tuesday, June 11th. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and an average price target of $82.12.

Shares of Tabula Rasa HealthCare stock opened at $54.25 on Friday. The firm has a market capitalization of $1.19 billion, a P/E ratio of 271.25 and a beta of 1.62. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 1.73. Tabula Rasa HealthCare has a 12-month low of $40.86 and a 12-month high of $91.16. The business’s 50-day moving average price is $48.02.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14). The firm had revenue of $60.96 million for the quarter, compared to the consensus estimate of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. On average, research analysts forecast that Tabula Rasa HealthCare will post -0.55 earnings per share for the current year.

In other news, CEO Calvin H. Knowlton sold 8,270 shares of the stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gordon Tunstall sold 1,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $52.60, for a total transaction of $52,600.00. The disclosure for this sale can be found here. Insiders sold 50,270 shares of company stock valued at $2,457,654 in the last three months. Company insiders own 11.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Handelsbanken Fonder AB acquired a new stake in shares of Tabula Rasa HealthCare during the 2nd quarter worth approximately $6,241,000. Marshall Wace North America L.P. grew its position in shares of Tabula Rasa HealthCare by 156.2% during the 1st quarter. Marshall Wace North America L.P. now owns 17,575 shares of the company’s stock worth $992,000 after buying an additional 10,715 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Tabula Rasa HealthCare during the 1st quarter worth approximately $172,000. Citigroup Inc. grew its position in shares of Tabula Rasa HealthCare by 2,337.1% during the 1st quarter. Citigroup Inc. now owns 309,588 shares of the company’s stock worth $17,467,000 after buying an additional 296,885 shares during the period. Finally, Meitav Dash Investments Ltd. grew its position in shares of Tabula Rasa HealthCare by 2.7% during the 1st quarter. Meitav Dash Investments Ltd. now owns 38,000 shares of the company’s stock worth $2,130,000 after buying an additional 1,000 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: Marijuana Stocks

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.